Palsonify (paltusotine) is the first once-daily oral drug for the treatment of acromegaly.[3][4] It is a selective somatostatin type 2 receptor agonist that controls elevated levels of the hormone IGF-1 in patients with acromegaly.[4] The drug normalizes IGF-1 levels within 2 to 4 weeks and keeps them at a controlled level.[2] The PATHFNDR-1 and PATHFNDR-2 clinical trials demonstrated that Palsonify effectively reduces symptoms of acromegaly and is well tolerated by patients.[3][5] The most common side effects include diarrhea (23%), nausea (13%), loss of appetite (10%), and irregular heartbeat (7%).[2] The European Medicines Agency (EMA) approved the application for registration in March 2025 and at the same time granted the drug an orphan designation.[3] Long-term data from extended phase studies confirm sustained control of IGF-1 and consistent safety of the drug.[7]